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Case presentation
A 29-year-old white female complained of intermittent dizziness and
was found to have a blood pressure of 180/120 mm Hg. The elevated
blood pressure was thought to be related to emotional factors, and
initially she was treated with tranquilizers. Three months later, the
blood pressure was 160/120mm Hg, and physical examination disclosed
a right upper quadrant and pen-umbilical bruit.
The patient was admitted to a local hospital, where an intravenous
pyelogram was normal, but a renal arteriogram showed a right main
renal artery stenosis and a normal left renal artery (Fig. 1). The
peripheral plasma renin activity (PRA) was 2.0 ng/mllhr and urinary
sodium excretion was 133 mEq/24 hr. Differential renal vein renin
values were 2.86 ng/mllhr from the right renal vein, 3.20 ng/ml/hr from
the left renal vein, and 3.25 nglml/hr from the inferior vena cava below
the renal vessels.
In view of the discrepancy between the angiographic and renal
venous renin values, the patient was referred to The New York
Hospital-Cornell Medical Center. All antihypertensive medications
were withheld and repeated renin studies were performed at the
Cardiovascular Center (Table 1). Oral administration of the angiotensin
converting enzyme inhibitor captopril resulted in a rise in peripheral
PRA to 76 nglmllhr after 90 minutes. Renal vein renins lateralized to the
right side with suppression of renin release from the normal left kidney,
(V-A)/A = 0.06.
The patient was then admitted to The New York Hospital, where the
blood pressure on admission was 150/95 mm Hg. The patient had
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smoked one pack of cigarettes daily for 7 years. Funduscopic examina-
tion was benign, and the previously described abdominal bruit was
audible. The remainder of the physical examination was unremarkable.
The BUN was 23 mgldl, serum creatinine concentration was 0.9 mg/dl,
serum potassium concentration was 4.2 mEq/liter, and the electrocar-
diogram was normal.
On the day following admission, she underwent successful translu-
minal renal angioplasty (Fig. 2). The blood pressure immediately fell to
120/70 mm Hg, and she was discharged 2 days after angioplasty. She
remains normotensive without antihypertensive medications two and
one-half years following angioplasty.
Discussion
DR. E. DARRACOTT VAUGHAN, JR. (Director, Division of
Urology, and James J. Colt Professor of Urology, The New
York Hospital-Cornell Medical Center, New York, New York):
This patient demonstrates the difficulty one encounters in
validating the high clinical suspicion of renovascular hyperten-
sion (RVH). The numerous clinical clues included her young
age, the sudden onset of severe hypertension, and the abdomi-
nal bruit characteristic of the entity [1] (Table 2). Moreover, the
renal angiogram showed a tight stenosis with characteristics
consistent with intimal fibroplasia or fibromuscular hyperplasia
[21, both progressive lesions [3, 4]. But the initial measurement
of plasma renin activity (PRA) failed to detect unilateral hyper-
secretion of renin from the suspect kidney.
I would like to direct my attention to two aspects of this case.
First, I hope to clarify why the initial renin values were
nondiagnostic and to develop an approach that will minimize
the perplexing problem of false-negative renin values in patients
with RVH [1, 5]. Second, I will review recent advances in the
management of patients with proven RVH, emphasizing the
newest modality of correction, transluminal renal angioplasty
[6], which was utilized in this case (Fig. 2).
The importance of establishing a cause-and-effect relation-
ship between unilateral renoparenchymal or renovascular dis-
ease was first emphasized by Homer Smith [71. He realized in
1948, following a literature review of reports from the prior
decade, that only approximately 19% of patients subjected to
nephrectomy for hypertension experienced sustained reversal
of their hypertension. The initial stimulus for nephrectomy had
been the work of Goldblatt and coworkers. In 1934 they
reported the production of hypertension in the dog following a
critical degree of renal arterial constriction, which reversed
after removal of the renal arterial clamp or of the kidney [8].
Soon thereafter Butler reported the first reversal of hyperten-
sion following nephrectomy in a patient with a small "pyelone-
phritic kidney" [9], and one year later Leadbetter and Burkland
reported another cure of hypertension in a child with pathologic
evidence of a renal arterial lesion [10]. There followed an
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must reduce blood flow by an amount sufficient to activate
renin release and thus initiate renovascular hypertension.
Hence a practical definition of renovascular hypertension is
hypertension resulting from a renal arterial lesion and able to be
relieved by correction of the offending lesion or removal of the
kidney.
It is not surprising that all renal arterial lesions do not cause
renovascular hypertension. In 1938 Mann and coworkers
showed that the internal diameter of the carotid artery could be
reduced by 70% before a significant fall in blood flow occurred
[19]. Similarly, Goldblatt realized that a critical degree of renal
arterial stenosis had to be achieved before pressure gradient
and flow reduction were sufficient to initiate hypertension. This
observation was carried further by Selkurt, who showed that a
40 mm Hg gradient across a renal artery stenosis was required
before a change occurred in renal plasma flow, glomerular
filtration, sodium excretion, and urinary flow rate [20]. In the
aggregate, these data indicate that knowledge of a patient's
renal vascular anatomy, although important as a guide for
choosing between transluminal angioplasty and surgical repair,
is not sufficient for predicting whether the blood pressure will
respond to correction of the obstructing lesion. All anatomic
lesions do not impair renal blood flow and do not induce renin
secretion.
Fig. 1. Right renal artery on selective arteriogram demonstrating main
renal artery stenosis.
aggressive yet disappointing clinical experience with nephrecto-
my for cure of hypertension in patients with unilateral renal
disease. This experience led to the search for a way of proving
that a renal lesion was actually causing the hypertension.
Smith's challenge resulted in studies of the effect of renal
artery constriction on renal function. In dogs, renal artery
constriction induced a marked decrease in sodium and water
excretion from the affected kidney [11, 12]. In 1954, Howard et
al utilized these observations to develop a differential renal
function test [13]. Based on bilateral ureteral catheterization,
the test could identify the "ischemic kidney." Another major
advance was the development of translumbar aortography and
demonstration of its value in visualizing renal arterial lesions
[14]. In 1957, the first large series of patients with renal arterial
lesions was reported [15].
The development of arteriography gave us an accurate means
of identifying renal arterial disease and heralded the subsequent
development of renal arterial vascular repair [161. This ap-
proach led to a renewed wave of enthusiasm for surgical
management of the disease. However, it soon became apparent
that normotensive patients undergoing arteriography for other
reasons often had renal arterial disease [171, and autopsy figures
subsequently confirmed the radiologic findings [181. According-
ly, the finding of renal arterial disease alone is not sufficient
justification for surgical correction in a hypertensive patient.
The anatomic lesion must be functionally significant; that is, it
Uncovering functionally significant
renal artery stenosis
Means by which patients with functionally significant renal
artery stenosis can be identified have proved more elusive than
might have been predicted. Certainly there are no pathogno-
monic clinical characteristics that lead to a reliable diagnosis
[21]. In many patients, none of the clinical clues are present to
prompt a definitive evaluation (Table 2). The variability of
clinical findings led to the development of a variety of ap-
proaches for identifying the patient with renovascular hyperten-
sion. As I previously mentioned, the observation in animals that
partial occlusion of the renal artery resulted in increased
fractional reabsorption of sodium and water and increased
concentration of nonreabsorbable solute led to the development
of differential renal function studies. Numerous techniques
based on these observations have evolved [221. The complexity
of the study precludes its practicality as a screening test,
however. The development of a reliable method for measuring
renin levels has almost eliminated the use of "split renal
function" studies. At present, differential renal function studies
are performed only if renal vein renin studies are equivocal or if
the patient has unilateral parenchymal disease. In the latter
case, renal function studies are utilized to determine that the
affected side contributes only minimally to overall renal func-
tion, assuring little loss of glomerular filtration following
nephrectomy [231. Thus, one should determine the glomerular
filtration rate of the diseased kidney before electing to remove
functioning nephrons.
The same physiologic principles that led to the development
of the 'split renal function" tests serve as the basis of the rapid-
sequence intravenous urogram [241 and radionuclide studies
[25]. Both studies produce only about 80% true-positive results.
However, the false-positive rates, approximately 11% and 25%
respectively, are too high, especially when approximately 90%
of the population being screened comprises patients with essen-
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Table 1. Studies with angiotensin II blockade
Blood pressure Peripheral plasma renin activity
mm Hg ng/mI/hr
Control 130/100 64 (1JNaV 80 mEq)
Pre captopril 120/95 5.4
Post captopril (25 mg)
30mm 110/70 63.0
60 mm 72.0
90 mm 76.0
Renal vein renin activity
nglml/hr
Pre captopril ® RV 3.1 © RV 1.7
IVC 1.6
(V_A)f® (V—A) OO6forQRV
Post captopril ® RV 27.0 rnj RV 13.0
IVC 12.0
(V—A) 1.25 for® RV (V—A) 0.O8for © RV
A = IVC value
tial hypertension. In summary, the rapid-sequence intravenous
urogram as well as the radionuclide studies have failed to
achieve suitable sensitivity to serve as reliable screening tests
for renovascular hypertension.
Indeed, it was the failure of these techniques, coupled with
the development of reliable methods of quantifying the compo-
nents of the renin-angiotensin-aldosterone system, that led to
the use of renin determinations for identifying patients with
renovascular hypertension. At this point it would be useful for
us to return to experimental animal models of renovascular
hypertension to define the characteristics of the disease in a
precisely controlled setting.
Mechanisms of experimental
Goldblatt hypertension
The initial work of Goldblatt stimulated a search for a clearer
understanding of the relationship between the renin system and
renovascular hypertension. The first advance was the apprecia-
tion that two distinct models of experimental Goldblatt hyper-
tension can be produced. In one model a renal artery is clamped
and the opposite kidney is left in place (the "two kidney, one
clip" model); in the other model, a renal artery is clamped but
the other kidney is removed (the "one kidney, one clip"
model). Although animals are equally hypertensive in both
models, the pathophysiology differs. In the one-kidney, one-
clip model, volume is expanded and PRA is normal or sup-
pressed [26]. In the two-kidney, one-clip model, PRA and renin
content are increased in the kidney with the stenosed artery and
decreased in the opposite kidney [27, 28].
The second advance resulted from the investigation of com-
.
Fig. 2. Right renal artery following percutaneous transluminalpounds that either block the conversion of angiotensin I to
angioplasty.
anglotensin II or antagonize specific All receptors [29, 30].
These drugs have been important both in providing insights into
the role of the renin-angiotensin-aldosterone system in the Knowledge of the structure of All and improved methods of
normal and abnormal state and, in the case of converting peptide synthesis led to the synthesis of many All analogues of
enzyme inhibitors, in treating renovascular hypertension. modified amino acid sequence. In the process, the discovery of
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Table 2. Clues suggestive of renovascular hypertension (RVH)
Historic clue Comment
Hypertension in the absence of family history of
hypertensive disease.
Suspect RVH if family history negative; however, about one-third of patients with
RVH have a positive family history.
Age less than 25 years or greater than 45 years. The average age of onset for essential hypertension is 31 10 (SD) years. Children
and young adults with RVH usually have fibromuscular disease. Adults over 45
years with RVH are more likely to have atherosclerotic narrowing of the renal
arteries.
Abrupt onset of moderate to severe hypertension. Whereas essential hypertension usually begins with a "labile" phase before mild
hypertension becomes established, RVH usually has a more abrupt natural
history, often first appearing as moderate hypertension.
Development of severe or malignant hypertension. RVH often becomes moderately severe and is prone to produce accelerated or
malignant phase hypertension; both forms of hypertension involve markedly
increased renin release.
Headaches Essential hypertension is usually asymptomatic. There seem to be more headaches
with RVH, possibly related to its severity, or high levels of angiotensin II, a
potent cerebrovascular vasoconstrictor.
Cigarette smoking In a recent survey, 74% of patients with fibromuscular renal artery stenosis were
smokers; 88% of those with atherosclerotic disease smoked.
White race RVH is uncommon in the black population [211.
Resistance to or escape from blood pressure control
with standard antihypertensive therapy
Probably the most typical feature of RVH is that it responds poorly to diuretics
and often only transiently to antiadrenergic drugs.
Excellent antihypertensive response to converting
enzyme inhibitors, e.g., captopnl.
Converting enzyme inhibitors block the renin-angiotensin system most effectively
and are therefore highly specific agents.
Clues from physical examination and
routine laboratory evaluation Comment
Retinopathy Hemorrhages, exudates, or papilledema indicate accelerated or malignant phase.
Abdominal or flank bruit A helpful clue, but are commonly present in elderly individuals, and occasionally
present in younger patients who have no apparent stenosis.
Carotid bruits or other evidence of large-vessel
disease
Commonly the vascular pathology is not limited to the renal bed.
Hypokalemia—in the untreated state or in response
to a thiazide diuretic.
Increased aldosterone stimulation by the renin-angiotensin system tends to reduce
the serum potassium level. In untreated essential hypertension this does not
occur. Thiazide diuretics accentuate this phenomenon in RVH.
a From Ref. 5.
analogues with differing biologic potencies led to an under-
standing of the contribution of each of the amino acid residues
to the action of All [311. Among the analogues synthesized
were two that had considerably reduced biologic activity as
agonists, but which also blocked the action of All on isolated
smooth muscle and in the intact animal. These derivatives were
[Phe4, Tyr8] All [32] and [Ala8] All [33]. Further modifications
led to the synthesis of the [sarcosine', Val5, Ala8] All deriva-
tive, saralasin [34]. The substitution of alanine at position 8
resulted in a severe reduction of agonist activity without a loss
of affinity for the receptor; the presence of sarcosine at the
amino terminus allowed for resistance to hydrolysis by pepti-
dases. These characteristics made saralasin a prototype of an
All receptor antagonist with a significant duration of action.
Since saralasin is not completely devoid of stimulatory biologic
activity (that is, it is a partial agonist), studies in which it is used
require careful evaluation [35].
Captopril (SQ 14,225, D-3-mercapto-2-methylpropanoyl-L-
proline) is an angiotensin converting enzyme inhibitor (CEI)
that is a clinically effective antihypertensive drug [36]. Its
synthesis followed by approximately 10 years the discovery of
several naturally occurring CEIs in snake venom [37]. The
active components of snake venom that were CEIs turned out
to be small peptides. Among a large number of synthetic
peptide analogues was the nonapeptide teprotide (SQ 20881),
the first CEI used in humans [38]. Although useful, teprotide
has limited effectiveness because of a lack of activity when
given orally. Further modifications led to the synthesis of
captopril.
The animal model of hypertension most analogous to human
renovascular hypertension is the one-clip, two-kidney Goldblatt
preparation. The hypertension in this model initially depends on
increased renin secretion from the kidney with the clipped
vessel, and leads to All formation and arteriolar vasoconstric-
tion. The administration of saralasin [30] or captopril [39] can
prevent or reverse the hypertension. This early state of one-
clip, two-kidney Goldblatt hypertension exhibits four charac-
teristics (Fig. 3): (1) increased renin secretion from the damaged
kidney; (2) absence of renin secretion from the opposite kidney;
(3) decreased renal blood flow to the damaged kidney; and (4)
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elevated blood pressure secondary to All-induced vasocon-
striction [40, 41].
It should be recalled that the blood pressure responsiveness
to acute All blockade in the early phase of the one-clip, two-
kidney model is transitory [39, 42]. The blood pressure in these
animals eventually becomes resistant to acute All blockade
unless the animals are subjected to a restriction in dietary
sodium. At this later stage, the animals resemble those with
one-kidney, one-clip, a model in which the hypertension rapidly
becomes resistant to All antagonists [30] or converting enzyme
inhibition (unless the animal is sodium depleted) [43]. However,
persistence of hypertension during acute All blockade does not
exclude fully an action of All in blood pressure maintenance. In
fact, chronic administration of captopril leads to a decrease in
blood pressure accompanied by natriuresis and diuresis in
saralasin-resistant" one-kidney, one-clip Goldblatt hyperten-
sive rats [44].
Using the animal data as a guide, we have found that patients
most likely to be cured following successful correction of a
renal arterial lesion exhibit the characteristics of the early phase
one-clip, two-kidney model (Fig. 3). The information gained
from the one-kidney model suggests that some patients will
benefit from successful revascularization even though they do
not meet defined preoperative criteria used to predict curability
[45]. It is not known whether these patients are analogous to the
chronic one-clip, two-kidney model. Correction of hyperten-
sion in these patients could be due either to restoration of renal
blood flow, glomerular filtration rate, and sodium excretion, or
to reversal of a presently ill-defined role of All in the presence
of normal PRA. It is estimated that 20% of patients with renal
artery stenosis whose hypertension is cured by renal angio-
plasty have normal peripheral PRA [41].
Criteria for identifying renovascular hypertension
Increased renin secretion—Peripheral plasma renin activity.
In the years after the initial work of Goldblatt, it was assumed
that excess renin secretion (which led to excess All formation)
was the underlying derangement in renovascular hypertension.
This hypothesis was challenged when circulating PRA was
found to be normal in animal models [46] and in a fraction of
patients with renovascular hypertension [45]. Indeed, peripher-
al PRA was found in retrospect to be elevated in only 109 of 196
patients (56%) in whom verified correction of renovascular
hypertension had been reported [45]. But careful review of the
original papers reveals that these samples often were obtained
under conditions now recognized to invalidate or limit accurate
interpretation of the data. For example, we now know that PRA
is inversely related to sodium intake and must be correlated in
some fashion with the state of sodium balance. Moreover,
virtually all antihypertensive drugs influence PRA and must be
stopped 2 weeks before blood sampling for PRA. Aids for
increasing the accuracy of determination of peripheral PRA are
shown in Table 3.
The rationale for emphasizing the peripheral PRA is that it
represents an index of renal renin secretion [47]. There is a
common misconception that differential renal vein renin mea-
surements by themselves can be used to evaluate whether renin
secretion is increased. In point of fact, actual renin secretion
(renal vein renin concentration minus arterial renin concentra-
tion multinlied by renal blood flow) is rarely determined clini-
cally. Obviously, a high renal venous renin concentration may
reflect increased or normal renin secretion depending on wheth-
er renal blood flow is normal or reduced, respectively; secretion
is a function of concentration times flow.
Increased renin secretion should be characteristic of renovas-
cular hypertension. Therefore, when samples are collected and
analyzed under exactly the same conditions, increased renin
secretion should be reflected by elevated peripheral PRA as
compared with PRA values obtained from normotensive con-
trols. Peripheral PRA (determined in blood collected at noon
after 4 hours of patient ambulation), when correlated with the
rate of urinary sodium excretion, is an excellent tool for
identifying abnormally high renin secretion. In a recent study of
patients who subsequently had successful transluminal angio-
plasty, the peripheral PRA was elevated in 80% of those studied
(Fig. 4). Moreover, the PRA always decreased, often to normal,
following successful renal angioplasty, thereby confirming the
hypothesis that the peripheral PRA is an indicator of increased
renin secretion due to renal artery stenosis [41].
Measurement of PRA in this manner (that is, PRA correlated
with sodium excretion) as a screening test for renovascular
hypertension has certain limitations. In addition to a 20% false-
negative rate in patients with proven renovascular hypertension
(as illustrated by the patient under discussion), there is a
technical problem. Many patients with renovascular hyperten-
sion have severe life-threatening hypertension or coexistent
heart disease, which precludes cessation of antihypertensive
medication prior to blood collection for peripheral PRA deter-
minations. As already noted, blood sampling while patients are
taking drugs invalidates the accuracy of the peripheral PRA as a
practical screening tool. In addition, 16% of patients with
essential hypertension also have high PRA [48]. Taken togeth-
er, these problems have led to the search for a better test to
detect renovascular hypertension.
Depressor response and reactive hyperreninemia following
administration of angiotensin II blocking agents. The first
angiotensin blocking agent used experimentally in human hy-
pertension was saralasin. The initial results demonstrated that,
as predicted, the compound did lower blood pressure in high-
renin forms of hypertension including the renovascular type
[49]. In the second wave of human studies with saralasin, the
partial agonist activity of the drug was exposed [50, 51]. Thus,
in clinical settings in which PRA was low, the drug actually
increased blood pressure. Moreover the blood pressure-lower-
ing effect of the drug was found to be inversely proportional to
sodium intake. Accordingly, although reasonably accurate in
identifying patients with renovascular hypertension [52], the
test's usefulness is limited because of the agonist effect of the
drug, the influence of sodium balance on the blood pressure
response to the agent, and the need for intravenous infusion.
A second approach to the use of angiotensin blockade in the
diagnosis of renovascular hypertension came from experience
with converting enzyme inhibitors. Teprotide was shown to
block the vasopressor effect of angiotensin I, and a close, direct
correlation between the pretreatment level of PRA and the
magnitude of the depressor response was demonstrated [531.
From these studies, it was predicted that converting enzyme
inhibitors might be useful in detecting angiotensin-dependent
forms of hypertension.
The successful exnerience with tenrotide was a ootent stimu-
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Table 3. Aids for increasing the accuracy of determinations of
peripheral plasma renin activity (PRA)
Problems Solutions
The "normal" value for
PRA varies from labora-
tory to laboratory.
Clearly understand the factors that
affect "normal" values in your labo-
ratory: time of sampling, state of
ambulation (upright posture influ-
ences PRA), state of sodium intake.
The method of collection of
blood samples from pa-
tients may vary from that
used to collect samples
designated to establish
normal range.
Utilize identical conditions for sam-
pling.
Patient is taking drugs; all
antihypertensive and diu-
retic drugs affect PRA.
Stop all treatment 2 weeks prior to
blood sampling for PRA.
PRA is inversely related to
sodium intake and excre-
tion.
Collect a 24-hr urine for sodium deter-
mination at the time that you collect
blood for PRA; use the sodium in-
take level that your laboratory uses
to define their normal range."
Inferior vena cava renin
used as "peripheral."
Obtain peripheral blood for PRA as
described on a day separate from
renal vein sampling.
"If a new methodology is being established, suggest the development
of a renal sodium index. (Adapted from Ref. 99.)
During the early studies of the antihypertensive effect of
these agents, angiotensin blockade was found to result in a
marked rise in PRA in selected patients. The induction of a
marked rise in plasma renin activity in 31 of 32 patients with
renovascular but in only 2 of 64 with essential hypertension
suggested that reactive hyperreninemia following All blockade
with intravenous agents was a more specific test for renovascu-
lar hypertension than was the induction of depressor responses.
These studies also revealed that prior sodium depletion, pro-
duced either by diuretics or by low-sodium diet, abolished the
specificity of this test [35].
With the availability of the oral converting enzyme inhibitor
captopril, single oral test doses instead of intravenous infusions
of saralasin or teprotide were employed with very similar
results [55]. An additional advantage of this approach was the
observation that patients with renovascular hypertension who
were being treated with a beta-adrenergic blocker still respond-
ed to oral administration of captopril with a fall in blood
pressure and a rise in PRA [56] (Fig. 5).
The protocol for using single oral doses of captopril to screen
for renovascular hypertension is shown in Table 4. In summary,
response to a single oral dose of captopril appears to separate
accurately patients with renovascular or renal parenchymal
hypertension from those with essential hypertension. In addi-
tion, a 24-hour urine collection is not necessary and the patient
can remain on treatment with beta blockers. Hence the test is
complementary to the renin-sodium index for identifying renin
hypersecretion.
lus to the development of captopril. Captopril, like teprotide,
has potential as a diagnostic probe; it acts rapidly—within 15
minutes—and reaches peak effect by 90 minutes [54]. Initial
studies showed a close relationship between the pretreatment
PRA and the magnitude of the depressor response to the first
dose of captopril [54].
Differential renal vein renin levels
Since the development of differential renal vein renin deter-
minations [57], the technique has emerged as the most useful
tool in identifying correctable renovascular hypertension. The
most common approach has been calculation of the renal vein
Elevated
peripheral
plasma renin
activity (PRA)lV
Drop in B.R with
anti-renin or
anti-angiotensin
II drugs
—- (Renal vein-arterial renin) = 0
(V-A)-0
Fig. 3. Characteristics rtf the early phase of two-kidney, one-clip Goldblait hypertension in the rat (left) and the criteria derived from the animal
model that identify the patient with correctable renal hypertension. (From Ref. 4.)
Fig. 4. Effect of angioplasty on peripheral
plasma renin activity indexed against 24-hour
sodium excretion. Left panel: before
angioplasty. Right panel: 6 months after
o angioplasty. Hatched area shows normal
range. (From Ref. 41.)
renin ratio, that is, stenotic divided by normal-side PRA values,
and comparison with some arbitrary "positive" ratio (usually
1.5:1). The major limitation in this method is in selecting a
"positive" ratio that accurately separates patients with reno-
vascular hypertension from those with essential hypertension
[45]. Generally, a renal vein renin ratio greater than 1.5 predicts
a fall in blood pressure following correction of the vascular
lesion in over 90% of patients. However, a negative ratio does
not preclude a successful response to revascularization. In the
review by Marks and Maxwell, 51% of patients with a negative
ratio (64 of 126) were cured by appropriate surgical intervention
[45]. However, these patients were a minority of the total
population studied, and the actual false-negative rate for the
entire group was 15% (64 of 412 patients).
In addition, blood collection for renal vein PRA involves
significant risk of sampling error due either to incorrect catheter
placement or to sampling from a renal vein that does not drain
the renal area supplied by the stenotic artery. Sampling from
the inferior vena cava below the renal veins is a safeguard
against this error, and the absence of a 50% renin increment for
the contribution from both kidneys identifies an inadequate
differential renal vein renin study [401. Accordingly, the first set
of renin values obtained for today's patient was not "negative"
but inconclusive.
Finally, a positive renal vein renin ratio does not exclude
bilateral renin secretion, albeit asymmetric, which would indi-
cate bilateral renal disease. In this setting, correction of a
unilateral lesion will not totally correct the underlying patholo-
gy, and complete blood pressure control will not be achieved.
Because of these limitations of the traditional renal vein ratio
analysis, another method for analyzing renin values was de-
vised. It is based on the characteristics of experimental two-
kidney, one-clip Goldblatt hypertension, as detailed in Table 5
and Figure 3 [40, 58].
Hypersecretion of renin, as determined by the renin-sodium
index or by captopril stimulation, serves as the primary criteri-
on for the diagnosis of renovascular hypertension. A second
criterion is the demonstration that renin secretion is absent
from the contralateral (or noninvolved) kidney. Suppression of
renin secretion from this kidney can be determined by subtract-
ing the arterial plasma renin activity (A) from the renal venous
renin activity (V). Because the inferior vena caval (IVC) renin
and aortic renin are the same, the IVC renin value can be
substituted for (A) in this equation [47]. Hence, patients with
curable renovascular hypertension exhibit an absence of renin
secretion from the opposite kidney, that is (V-A) = 0, also
termed "contralateral suppression" of renin [40, 59]. Contralat-
eral suppression of renin indicates that the noninvolved kidney
is responding in an appropriate, "normal" fashion to the
elevated blood pressure, increased circulating angiotensin II
levels, and/or increased sodium chloride at the macula densa by
shutting off renin secretion. This phenomenon is present not
only in patients with unilateral renal arterial lesions but also, on
occasion, in patients with bilateral disease demonstrated by
arteriogram who have a dominant lesion on one side [60].
A third criterion is based on studies of renal vein and arterial
renin relationships in patients with essential hypertension. The
mean renin level in the renal vein has been determined to be
about 25% higher than the arterial PRA [47]. Hence, a total
renin increment (both kidneys) of approximately 50% is neces-
sary to maintain a given peripheral renin level, (V-A)/A = 0.50.
A reduction in renal blood flow also influences the renal venous
renin level, however. In this setting, the renin concentration in
the renal vein will be misleadingly high, shifting the renal vein-
to-arterial renin relationship upwards. Thus the degree to which
the increment exceeds approximately 50% becomes an index of
the severity of the reduction in blood flow consequent to the
obstructing vascular lesion (Fig. 6, Table 5). The combination
of these criteria found in a group of patients managed by renal
revascularization is shown in Figure 7 [611.
The sensitivity and specificity of these criteria in predicting
curability have been studied in a group of 46 hypertensive
patients with arteriographically proved unilateral renal artery
stenosis who underwent successful angioplasty [41]. In the
subgroup of 34 patients with technically acceptable renin val-
ues, there were 23 true positives, no false positives, 3 true
negatives, and 8 false negatives. Of the 8 false negatives, 4 had a
(V-A)/A between 0.40 and 0.48, and 6 showed contralateral
suppression. Only 2 patients had symmetrical renal vein renin
values [41]. The present approach thus gave a sensitivity of 74%
and specificity of 100%, better indices than those produced by
renin ratio analysis. An additional aid to renal vein sampling is
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The use of converting enzyme inhibition to
increase the accuracy of renal vein renin analysis
Fig. 5. Levels of plasma renin activity in renovascular and essential
hypertension 90 minutes after a single dose of captopril. A marked
reactive hyperreninemia was found in the group with renovascular
hypertension whether or not they were already receiving beta-blocker
therapy. (From Ref. 56.)
Table 4. Single-dose captopril test
Drugs
The patient should receive no medicines for at least 2 weeks if
possible. Otherwise, continue a beta blocker but no diuretics,
converting enzyme inhibitors, or nonsteroidal antiinflammatory
drugs for at least 1 week, ideally 2 weeks.
Diet
A diet with normal or high sodium content is needed. Too low
a sodium intake produces false-positive results. If there is a
question about diet, a 24-hour urine collection for sodium will
closely reflect the intake.
Procedure
1. The patient may be supine, semirecumbent or seated for the
test, but measurements must be made with the patient in the
same position.
2. After measurements of blood pressure are stable (this usually
takes about 10—20 minutes), a blood sample for plasma renin
activity is drawn (in lavender-top Vacutainer kept at room
temperature).
3. Crush a 25mg tablet of captopril (to ensure that it dissolves) and
pour in water to produce a suspension of about 30 ml. Instruct
the patient to drink the suspension, wash the contents out
twice, and drink those also.
4. Remeasure blood pressure and PRA after one hour.
a From Ref. 5.
segmental renal venous sampling [62], especially when sam-
pling of blood from the major renal veins fails to demonstrate a
combined renin increment of 50% from both kidneys and
suggests either a technical error or segmental disease (Table 5).
Following the initial report of renin stimulation by angioten-
sin blockade [631, several groups have reported that converting
enzyme inhibition increases renin release from the ischemic
kidney [64, 65]. The magnitude of these induced changes is
shown in Figure 8. These data were derived from 26 patients
with unilateral renovascular hypertension. Not shown in this
illustration is the observation that the inferior vena cava levels
were comparable to those values measured from the normal
side; this finding reveals the continued suppression of renin
secretion from that kidney even after stimulation. Although
more information is required for us to distinguish the subtleties
(such as bilateral renovascular disease, branch lesions, total
occlusions, or coexisting renal parenchymal disease), current
evidence suggests that renin stimulation adds to the analysis in
certain specific situations: (1) when patients are already taking
drug therapy, for example, beta blockers, and the renin levels
are generally reduced; (2) when there is a question about the
reliability of the PRA measurements, particularly of low levels;
(3) when experience performing renal vein renins is limited and
subject to sampling errors; and (4) when equivocal values
already are present. We anticipate that the addition of convert-
ing enzyme inhibition during renal venous sampling for renin
will virtually eliminate the false-negative analyses that previ-
ously have limited the accuracy of the studies.
Anatomic confirmation of the renin criteria
Virtually the entire evaluation of the hypertensive patient
now can be accomplished without hospitalization, and much of
the expense previously precluding evaluation can be avoided
[66, 67]. We have performed more than 300 renal vein renin
samplings on outpatients; 100 of these samplings were accom-
panied by digital intravenous angiography (DIVA), a technique
that is approximately 90% accurate in identifying renal arterial
lesions [68]. We utilize a central injection for the DIVA to better
define the renal vasculature. The DIVA technique does not yet
adequately visualize branch or segmental disease involving the
smaller renal vessels.
Accordingly, DIVA can be utilized after renal vein sampling
for renin to give anatomic definition of the renal vasculature,
and for monitoring patients after correction of a renovascular
lesion [6]. The only caveat is that the DIVA only demonstrates
anatomic vascular disease; the functional significance of the
lesion still must be demonstrated.
Identifying the potentially curable patient
Our current approach is outlined in Figure 9. Any patient
with fixed hypertension whose blood pressure is refractory to
diuretic therapy is a potential candidate for this protocol,
because we believe that nearly all patients with renovascular
hypertension can be best managed by angioplasty or revascular-
ization. With respect to this empiric protocol, it could be argued
that highly suspect patients could be screened initially with a
digital angiogram. However, the functional significance of an
anatomic lesion with respect to ischemia inducing renin release
still must be established, so we routinely begin by determining
the peripheral PRA.
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Collection of samples (moderate sodium intake 100 mEq/day)
1. Ambulatory peripheral renin and 24-hour urine sodium excretion under steady-state conditions (i.e., not on day of arteriography).
2. Collection of blood for PRA before and after converting enzyme blockade.
3. Collection of samples for PRA in the supine position:
a. From suspect kidney (V1) and inferior vena cava (A1).
b. From contralateral kidney (V2) and inferior vena cava (A2).
4. Enhancement of renin secretion by converting enzyme blockade if initial renin sampling is inconclusive.
Criteria for predicting cure
High PRA in relation to UNaV
Contralateral kidney: (V2—A2) = 0
Suspect kidney: (V1—A1)/A1 = 0.50
(V1—A1)1A1 > 0.50
In patients with high PRA, (V1—A,)/A1 + (V2—A2)1A2 < 0.50 means:
a) Incorrect sampling
b) Segmental disease Repeat with segmental sampling.
a From Ref. 5.
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Fig. 7. Of 15 patients with renovascular hypertension, 13 exhibited (V-
A)/A in excess of 48% from the suspect kidney and a suppressed value
from the contralateral kidney. V is renal venous PRA: A is arterial or
infrarenal inferior vena cava PRA. Asterisks denote the 3 patients who
had values suggesting surgical curability yet who had residual or
recurrent hypertension due to technical failure. The other patients were
cured. (From Ref. 61.)
Fig. 6. Renal vein renin diagnostic patterns. In essential hypertension
(top), at all levels of renin secretion, the renin level in each renal vein is
about 25% greater than either the peripheral arterial or venous levels. In
the setting of unilateral renin secretion (curable renovascular hyperten-
sion), the active kidney is solely responsible for maintaining the
peripheral renin levels. Hence, the increment is 50% (0.5) and becomes
progressively greater as the renal blood flow is reduced. Unequal
bilateral renin secretion (bottom right) indicates bilateral disease and
decreases the chance of cure following corrective unilateral surgery.
(From Ref. 100.)
In our experience, a low PRA is rarely found in untreated
patients with nonazotemic renal arterial disease; therefore we
do not usually continue the evaluation in these patients unless
their hypertension is refractory to treatment. Patients with high
or normal PRA undergo a "peripheral" captopril test (Table 4).
The test cannot be performed if the patient is taking captopril
chronically. If the test is positive, the differential renal vein
sampling and digital angiography are performed together. The
sampling procedure is ideally done first; then the catheter is
advanced into the superior vena cava for injection of contrast
material. This combined study is performed in the radiology
suite. After the study, the patient lies quietly in the Hyperten-
sion Unit for 2 to 4 hours before returning home.
If the diagnostic criteria are met, the patient is hospitalized
briefly for selective arteriography and percutaneous translu-
minal angioplasty. We continue to believe that the functional
significance of a renal artery lesion must be identified before we
intervene for therapeutic purposes.
Medical therapy for renovascular hypertension
The rationale for identifying patients with renovascular hy-
pertension is that their management differs from the treatment
offered patients with essential hypertension. Indeed, hyperten-
sion of renal origin is difficult to manage with conventional
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Table 5. Renin values for predicting curability of renovascular hypertension'
Measurement of hypersecretion of renin.
An indicator of absent renin secretion from the contralateral kidney.
An indicator of unilateral renin secretion.
Measurement of reduced renal blood flow.
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0
a Sampling error
Technical failure
0.48
Essential hypertension
Renovascular hypertension
Incurable
v1-IvC >0
Should be 0 for curability
Normal renin
lVCK
V1-IVC
IVC
High renin
cçto
VçIVC - VrIVC
—j— — 0.25 = 0.25VrIVC0.25 —j—- 0.25
Curable
V1-IVC = 0 V2-IVCIVC = 0.5
Peripheral PRA high
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Fig. 8. Renal vein renin determinations (renal vein levels only) in
patients with documented renovascular hypertension before and after
captopril stimulation. Captopril accentuates renin secretion from the
ischemic kidney. Not shown are the inferior vena cava levels which are
the same as the levels measured from the normal side both before and
after captopril stimulation. (From Ref. 5.)
antihypertensive drugs. In a randomized study, morbidity and
mortality were greater in patients with renal hypertension
treated medically as contrasted with those treated surgically
[691.
With the development of better and more specific antihyper-
tensive drugs such as converting enzyme inhibitors and beta
blockers, however, we can now treat cases of renovascular
hypertension more effectively than ever before. Certainly in our
early experience, captopril appears effective in controlling
blood pressure in patients who are poor surgical candidates.
Although more specific anti-angiotensin medical management is
attractive, it is becoming increasingly apparent that sudden
normalization of blood pressure can lead to rapid progression of
renal insufficiency and total renal arterial occlusion [70]. In-
deed, reversible renal failure has been noted in patients with
renovascular disease treated with captopril [71, 721. Moreover,
less dramatic reductions in renal function have been observed
in patients with renovascular hypertension randomly selected
for nonoperative management, even in patients with acceptable
blood pressure control during the period of observation [73].
In addition the limited data available suggest that many
patients with either atherosclerotic disease [741 or fibromuscu-
lar disease [3] will have progressive disease. However, it has
been impossible to predict from the initial renal arteriograms
which lesions would actually progress [2]. The important ques-
tion of progression was addressed by Schrieber and coworkers,
and more precise information is now available [41. Serial
angiographic studies over a mean interval of 52 months in 85
patients with atherosclerotic disease revealed progressive vas-
cular obstruction in 37 patients (44%). Total arterial occlusion
occurred in 14 patients and was most common in patients with
greater than a 75% stenosis on the initial arteriogram. As would
be expected, a decline in renal function was more common in
the patients with progressive disease. Accordingly, the authors
suggested that renal revascularization might be indicated for
preservation of renal function in patients whose advanced
atherosclerotic disease was a major threat to overall renal
function. These patients are characterized by azotemia and
high-grade stenosis or stenosis involving a solitary kidney [4].
Sixty-six patients with medial fibroplasia were also followed for
a mean interval of 45 months. Progressive renal arterial obstruc-
tion was observed in 22 patients (33%); however, in no instance
did obstruction progress to total occlusion. Of particular inter-
est was the similar development of progressive disease in
patients greater than 40 years of age (15 of 46). Previously it had
been believed that the disease was stable in this age group [31.
Despite the progression demonstrated on angiogram, increases
in serum creatinine or reduction in renal size seldom occurred.
Accordingly, the authors did not suggest renal revascularization
for preservation of renal function in this group.
These collective observations make a strong argument
against noninterventive management in a patient with known
renovascular disease, especially in view of the increasing
success of percutaneous transluminal renal angioplasty [6] and
operative renal revascularization [75]. Further information is
needed to address the question of angioplasty or revasculariza-
tion of renal arterial lesions for the preservation of renal
function even in the absence of the criteria for patient selection
described herein or perhaps even in the absence of hyperten-
sion [4, 70].
Surgical management of renovascular hypertension
The first operative cure of hypertension followed unilateral
nephrectomy [9]. Today the indications for primary nephrecto-
my, rather than a procedure that preserves renal function, are
limited. Nephrectomy is utilized only (1) if renal function is
poor or absent in a small kidney (<8 cm in length); (2) in poor-
risk patients; (3) if uncorrectable vascular or parenchymal
disease is present; and (4) following occlusion of an attempted
revascularization (secondary nephrectomy). Partial nephrecto-
my can be utilized if there is stenosis of one of multiple renal
arteries or of a branch, but revascularization is preferable.
Endarterectomy was the first revascularization procedure de-
scribed as an alternative to nephrectomy; aortorenal bypass
utilizing the saphenous vein or hypogastric artery is now the
most commonly utilized surgical technique. In the Cooperative
Study on Renovascular Hypertension, the blood pressure re-
sponse to operative treatment of 502 patients was 51% cured,
15% improved, and 34% failed [76]. When the study was
conducted, however, renin determinations were not available
for proper patient selection, and postoperative arteriograms
were not performed in all patients whose blood pressures failed
to respond. These shortcomings notwithstanding, several
points are clear. Patients with fibromuscular disease had a
favorable blood pressure response (80%) more commonly than
did patients with atheromatous disease (63%). Moreover, pa-
tients with bilateral atheromatous disease had a less favorable
response (56%) and a high mortality rate (10%). The overall
mortality rate was 6%, with a preponderance of deaths in
patients with atheromatous disease (9.3%) in contrast to those
with fibromuscular disease (3.4%). Other significant risk factors
included the presence of atherosclerotic coronary artery dis-
ease and serum creatinine levels of greater than 1.4 mgldl.
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In contrast, recent surgical results are far superior, most
likely because of more rigorous selection of patients, owing to
criteria similar to those I have described, and to correction of
preexisting coronary and carotid disease prior to renal revascu-
larization. A compilation of surgical results taken from the
review by Stanley in Rutherford's text is shown in Table 6 [75].
In addition, the secondary nephrectomy rate is considerably
lower than that previously reported in the cooperative study.
We know that renal revascularization yields a low incidence of
late graft occlusion or restenosis (10%); this information is not
yet available in patients who have been managed with success-
ful transluminal angioplasty, however.
Percutaneous transluminal angioplasty
Dotter first described angioplasty in 1964 for the treatment of
atheromatous peripheral vascular disease. Not until Gruntzig
developed a reliable balloon catheter, however, was the tech-
nique widely used clinically. He described the first successful
dilation of a renal artery in 1978 [77]. Subsequently there have
been continuous modifications of techniques and catheters and
the procedure has been applied widely. Early results from
various series as compiled by Sos in a recent review are shown
in Table 7 [78]. Table 8 contains the results of our experience in
89 patients with an average follow-up of 16 months [61.
The technique is most successful in patients with fibromuscu-
lar disease. In the presence of atheromatous disease, an occlud-
ed renal artery, ostial stenosis at the aortic wall, or multiple
renal artery involvement were factors that markedly limited the
technical success of angioplasty. In contrast, the technical
success rate was 75% in nonocciuded, nonostial atherosclerotic
lesions. The blood pressure benefit was least in patients with
bilateral atherosclerotic disease.
The complication rate of angioplasty in our institution has
been low [6]. Complications include three incidents of puncture
site trauma necessitating repair and six renal artery dissections.
Four patients underwent successful revascularization, one had
no vascular impairment, and there was one late nephrectomy. It
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Fig. 9. Evaluation plan for identifying patients
with curable renovascular hypertension.
(From Ref. 101.)
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Table 6. Results of surgical treatment of renovascular hypertensiona
Medical Center
Patients with Patients with
Postoperative status
(%)C
•Failure
(including
Operative
mortality
fibrodysplasia arteriosclerosis Cure Improvement deaths) rate (%)
University of Michigan (1961—1980) [80] 178 135 47 42 11 1.9
University of California, Los Angeles (1958—1977)
[81] 335 168 64 23 13 (2.1)
University of California, San Francisco (1963—1974)
[82, 83] 42 84 39 34 27 1.6
Vanderbilt University (1961—1972) [84] 44 78 59 31 10 5.4
Cleveland Clinic (1962—1978) [85—88] 92 133 50 34 16 3.1
Baylor College of Medicine (1959—1979) [89] 113 376 36 29 35 1.8
From Ref. 75. Criteria for blood pressure response defined in cited publications. Most criteria paralleled standards of Cooperative Study on
Renovascular Hypertension. Results based on 568 operations, including 230 partial or total nephrectomies, except for mortality rate, which applies
only to 142 cases treated between 1972 and 1977. Data represent approximations from overlapping publications. Less detailed review of more
experience documented more than 90% of cure or significant improvement in successful operations, with a mortality rate of only 0.5% in 200
consecutive renal artery reconstructions unaccompanied by concomitant extrarenal vascular procedures such as aortic reconstructions, Data are
from nonconsecutive publications reporting specific operative approaches and are not representative of the entire Cleveland Clinic experience.
is our contention that the high short-term success rate, coupled
with the low complication rate, renders percutaneous translu-
minal angioplasty the current treatment of choice as the initial
intervention in patients with all forms of renovascular hyperten-
sion. Moreover, we believe that if angioplasty fails, reconstruc-
tive surgery should be performed.
In addition to witnessing a favorable clinical response to renal
angioplasty, we also have had the unique opportunity to study
the effect of restoration of blood flow on renal vein renin
concentration and renin secretion [41, 79]. To accomplish this
goal, we monitored the immediate effect of successful angio-
plasty on renal renin secretion. Thirty minutes following angio-
plasty, there was a marked reduction in the renal vein renin
from the previously stenotic side (Fig. 10). The residual ipsilat-
eral increment of renal vein renin was about 50% above the
peripheral level, whereas contralateral renin suppression per-
sisted. This 50% increment had been predicted previously to
occur in the setting of unilateral renin secretion and normal
renal blood flow [47].
Several months after angioplasty, the peripheral PRA de-
creased to normal in most patients; this result indicated a
reduction in renin secretion (Fig. 4). Of equal interest was the
restoration of a bilateral renin increment of approximately 25%
above the inferior vena cava renin level (Fig. 10). Hence,
contralateral renin suppression reversed after successful angio-
plasty. This 25% increment from both kidneys is characteristic
of the renin secretory pattern in patients with essential hyper-
tension [47]. The finding that the renal renin secretory charac-
teristics of renovascular hypertension reverse and that hyper-
tension is modulated after successful angioplasty is strong
support that these characteristics truly reflect the abnormal
secretory behavior of renin in curable renovascular
hypertension.
Questions and answers
DR. NIcoLAos E. MADIA5: Thank you, Dr. Vaughan, for an
excellent discussion. Do you advocate that only those patients
with hypertension, renovascular stenosis, and lateralized renal
vein renins should undergo angioplasty? The fact that the renin
criteria you use had a sensitivity of 74% in predicting a
Table 7. Results of angioplasty series for treatment of renovascular
hypertensiona
Cured
%
Im-
proved
%
Failed
%
Deaths
%
Nephrec-
tomy
% n
Fibromuscular
Author"
Mahler [90] 83 17 0 0 0 6
Kuhlmann [91] 67 33 0 0 0 13
Geyskes [92] 48 48 5 0 0 21
Grim [941 47 35 18 0 6 17
Sos[6] 59 33 7 0 3 27
Atherosclerotic
Author"
Mahler [90] 13 63 25 0 0 8
Schwarten [93]C 44 48 8 0 0 52
Kuhlmann [91] 35 57 8 0 0 24
Geyskes [92] 9 43 48 2 0 44
Grim [94]" 4 36 60 20 20 25
Sos [6]C 25 45 30 0 0 20
From Ref. 78.
Number in brackets refers to reference.
Includes patients with fibromuscular stenoses.
"Results from 4 year follow-up.
C Results for complete and partial success in unilateral disease.
favorable outcome indicates that you employed angioplasty in
several patients who failed to satisfy these criteria [41].
DR. VAUGHAN: In general, we find that most people evaluat-
ed, especially if they have a positive "peripheral captopril
test," have lateralizing renal vein renins. However, we still
perform angioplasty in patients without lateralization if our
clinical suspicion is strong. In two settings the renin data are
often uninterpretable. The first is when the inferior vena caval
renin is less than 1 ng/ml/hr, often because of the administration
of renin-lowering drugs. Second, patients who take captopril on
a chronic basis have a high IVC renin level, and the ipsilateral
renin increment usually does not fulfill our criteria; we are not
sure why this occurs [41]. It is of interest that suppression of
renin secretion from the contralateral kidney persists despite
the reduction of blood pressure (and presumably angiotensin II)
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Success
Failure
Total
Success
Partial success
Failure
Total
Success
Partial success
Failure
Total
Atherosclerotic disease
Success
Partial success
Failure
Total
Success (both sides)
Partial success (both
sides)
Partial success (one
side)
Failure
Totals
a From Ref. 6.
No. (%) Cured
Unilateral stenosis
24 (85.7) 13
4 (14.3) 0
28 (100) 13 (46.4)
Bilateral stenosis
3 (100) 3
0 (0) 0
0 (0) 0
3 (100) 3 (100)
Unilateral plus bilateral
27 (87.1) 16
0 (0) 0
4 (12.9) 0
31(100) 16 (51.6)
Unilateral stenosis
17 (56.7) 5
3 (10) 0
10 (33.3) 0
30 (100) 5 (16.7)
Bilateral stenosis
2 (9.5) 2
2 (9.5) 0
10 (47.7)
7 (33.3)
21(100)
9
0
9 (32.2)
2
4
6(21.4)
0 0
0 0
0 0
0 0
9
0
0
9 (29)
2
0
4
6 (19.4)
Table 8. Results following transluminal angioplasty"
Technical result
Fibromuscular disease
Blood pressure benefit
Fibromuscular
Improved Failed
2.0
1.5
Atheroma
0.5
0
—0.5
I I I I
Pre 30mm 6mo Pre 30mm 6mo
post post post post
ap<0.05
9
0
0
9 (30)
3
3
10
16 (53.3)
Fig. 10. Effectof angioplasty on renal vein renins. Samples were taken
immediately before angioplasty, 30 minutes after, and 6 months after.
The higher values correspond to the ischemic kidney, the lower to the
contralateral kidney. Asterisk indicates significant difference between
the 2 kidneys, and the dotted line is the normal level of (V-A)IA (0.24).
(From Ref. 41.)
0 0
DR. JEROME P. KASSIRER: I believe there is a unifying
management strategy for the application of percutaneous renal
0 2 angioplasty based on factors such as the efficacy of the proce-
dure and its risks. I will try to illustrate this strategy by referring
0 1 9 to two types of patients at opposite ends of a spectrum. In the
(9 5) (4 8) (85 7)
young patient with severe hypertension and renal artery steno-
sis, percutaneous angioplasty is quite likely to be beneficial.
Even if tests fail to document conclusively that the stenosis is
functionally significant, angioplasty might be warranted be-
cause the risks in the young are quite small. On the other hand,
in older patients with renal artery stenosis and progressive renal
failure, life expectancy is limited by disease of other organs,
complications of angioplasty are more frequent, and the effica-
cy of angioplasty in preventing progressive renal failure proba-
bly is rather low. In this group with low benefits and high risks
of angioplasty, we should use the procedure only for well-
documented indications. I have personally seen enough compli-
cations in this latter group to be wary of angioplasty. This
unifying strategy involves weighing for each patient the efficacy
and risks of the procedure against alternative approaches
including no therapy, drug therapy, and even surgical therapy.
To do this, of course, we need data not currently available.
DR. VAUGHAN: I agree and often state that we are in an era of
"tailored" therapy for patients with renovascular disease. My
concerns with medical management are progression of anatom-
ic disease, even in the face of blood pressure control, which
appears to be more common than we previously realized [4],
and deterioration of renal function due to the antihypertensive
treatment [70].
Dr. Kassirer: What do you do in the older group with bilateral
renal artery stenosis and moderate renal failure?
DR. VAUGHAN: If the patient has lateralization of renin
secretion, which is often the case [60], we would attempt an
angioplasty only on that side. If the blood pressure is not
controlled, however, then the other side would be dilated.
during captopril therapy. I am not sure we understand the
mechanism of contralateral suppression in these patients.
DR. MADIAS: My position is that given the evidence that large
numbers of patients have experienced a favorable response to
surgical management despite the absence of a lateralized renal
vein renin profile, and in view of the relatively low risk of
angioplasty, we have little ground for withholding the proce-
dure from such patients.
DR. VAUGHAN: Let me try to respond to that comment. The
"false-negative" rate utilizing older methods of interpretation
was about 15% [45]. Therefore, as you state, if we require
lateralizing renin levels, we will deny some patients a curative
procedure. However, we believe that with current methods,
and most especially with the use of converting enzyme inhibi-
tion, most patients with a hemodynamically significant renovas-
cular stenosis will have a lateralizing test. We also feel that the
person with a negative test should be warned before the
procedure that successful angioplasty might not correct the
hypertension. It will be interesting to study a large series of
patients who had nonlateralizing renin levels yet who were
treated by angioplasty. The chronic two-kidney, one-clip
Goldblatt rat model with normal renin secretion and blood
pressure resistance to acute but not chronic angiotensin II
blockade [441 suggests that a subset of patients might exist
whose blood pressure would respond to successful angioplasty
despite negative renin studies.
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However, the success rate of angioplasty is low and the patient
may require renal revascularization. The problem is that this is
a group of patients at high risk for various cardiovascular
complications regardless of the type of treatment chosen for
their renal arterial disease. There are now a number of prelimi-
nary studies, albeit without appropriate controls, showing the
benefit of successful angioplasty or revascularization for the
preservation of renal function in azotemic patients. This is an
exciting area and warrants further study.
DR. MADIAS: We have reported on a group of 12 patients with
marked renal functional impairment, severe hypertension, and
critical renovascular stenoses in a solitary functioning kidney or
bilaterally who underwent angioplasty primarily for preserva-
tion of renal function [95]. Over short-term follow-up, the
procedure appeared to result in stabilization or modest im-
provement in renal function in 7 of the 11 patients in whom
some technical success had been achieved. Unfortunately,
further follow-up indicated that several of the patients subse-
quently succumbed to cardiovascular or cerebrovascular
disease.
DR. VAUGHAN: Your experience with cardiovascular compli-
cations is supported by that of the earlier cooperative study [76]
and the experience at the Cleveland Clinic, which we have
alluded to.
DR. VIcToR G. MILLAN (Chief, Division of Cardiovascular
Radiology, NEMC): Thank you for your excellent presentation
and commentary. I want to pay tribute to Dr. Andreas GrUnt-
zig. He developed the balloon catheter following the pioneer
work by the American radiologist Dr. Charles Dotter, who first
published his experience in dilating arteries in 1962. In addition,
I would commend Dr. Alan Callow of our Vascular Surgical
Service for his foresight and early support of my use of this
technique. His referral of a patient in February 1978 resulted in
the first renal angioplasty performed here. What followed has
become the most exciting therapeutic maneuver in interven-
tional radiology. Percutaneous transluminal angioplasty has
provided a much needed, simple, low-risk method for curing
renal vascular hypertension and/or preserving renal parenchy-
ma by restoring renal blood flow.
On the question of selection of patients for PTRA, we are
beginning to look at our total experience of more than 130
patients. On the basis of incomplete analysis there is no doubt
about the young woman with fibromuscular disease, nor about
the healthy oldster with isolated renal artery stenosis. The
question yet unanswered concerns the patient with renal artery
stenosis in the presence of severely impaired renal function.
DR. JOHN T. HARRINGTON: Was the age-associated increase
in complications from PTRA documented?
DR. VAUGHAN: The failure and complication rates are higher
in the older patients, but I believe that this is due to the nature
of their disease, not age per se. The failure rate of angioplasty is
greatest in three settings: ostial disease, total renal artery
occlusion, and disease of multiple vessels. These are all athero-
matous conditions occurring in the older patients in contrast to
the younger patients with fibromuscular disease.
DR. MADIAS: Do you expect changes in balloon-catheter
specifications to lead to better technical success of the angio-
plasty procedure, especially regarding ostial lesions?
DR. VAUGHAN: Yes, Tom Sos certainly feels this way, and
his recent results in patients with difficult lesions are better than
those previously reported [78]. He believes that "overdilation"
of the offending lesion is very important in patients with
atherosclerotic disease and does not lead to increased
complications.
DR. ANDREW S. LEVEY (Division of Nephrology, NEMC):
What is the sensitivity and specificity of digital subtraction
angiography for diagnosing atheromatous and fibromuscular
renal artery lesions?
DR. VAUGHAN: The initial studies indicated about 90%
accuracy [68]; however, more extensive experience has been
somewhat disappointing. Perhaps we have asked too much of
the procedure. It is an easily performed adjunct to the collection
of renal vein samples for renin and we employ the tests
together, utilizing outpatient facilities in most cases. We realize
that the study may miss ostial, branch, and parenchymal
lesions, but it often gives valuable anatomic information. I
would like to emphasize that digital angiography gives only
anatomic information and the functional significance of the
lesion still needs to be proved.
DR. MILLAN: We too started out with great expectations for
intravenous digital subtraction angiography. But we found that
as an imaging modality it is often erroneous and inconclusive.
The reason is the delay between the injection of contrast
medium in the vena cava or right atrium and its arrival in the
renal arteries, during which there has been peristaltic activity or
the patient has moved, This delay results in motion artifacts and
images of poor quality.
We also perform selective renal vein renin determinations on
an outpatient basis. But I think that the arterial injection of
contrast material, which can be done in outpatients, is far
superior to intravenous injection. The filming can be performed
conventionally or digitally. Thus, outpatients can be provided
with a procedure that has high sensitivity and specificity at less
cost and a minimal, if any, increase in risk.
DR. GRANNUM SANT (Department of Urology, NEMC):
Would you comment on the cost savings of doing a transluminal
angioplasty versus surgical revascularization?
DR. VAUGHAN: We have not done a specific cost accounting
study but it should be performed. However, in contrast with
prior evaluation and operative treatment of renovascular hyper-
tension, which was very expensive [66, 67], the costs of
treatment with PTRA now are considerably less. The entire
evaluation, as I described, is usually performed without hospi-
talization, and hospitalization for the angioplasty often is for
only a few days. Accordingly we are aggressive in our search
for patients with potentially curable renovascular disease.
DR. RONALD D. PERRONE (Division of Nephrology, NEMC):
Some reports have suggested that the response to captopril over
several weeks may be a better predictor of surgical outcome
than the acute response [96, 97].
DR. VAUGHAN: We have utilized the concept of "pharmaco-
logic probes" to identify subsets of hypertensive patients since
Fritz BUhler showed the direct relationship between the blood
pressure response to propranolol and its renin-lowering effect
[98]. As you are aware, saralasin and teprotide also have been
used as probes. My concern with chronic captopril administra-
tion is that I would predict that a number of patients with
essential hypertension also would have a very good long-term
response. I certainly agree that a lack of blood pressure
response to captopril in a nonazotemic patient is rare in the
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patient with renovascular hypertension.
DR. MADIAS: Do you think that the relative benignity of the
angioplasty procedure and the progressive nature of fibromus-
cular disease justify performing the procedure in normotensive
patients who are found in angiography (for example, during
evaluation for kidney donation) to have fibromuscular disease
of only moderate severity?
DR. VAUGHAN: This is a fascinating question and will be
studied more and more in the future. We have dilated an
anatomic lesion in a normotensive patient prior to contralateral
nephrectomy for renal cell carcinoma. However, at present, we
do not advocate angioplasty in the normotensive patient. The
problem is that we do not have any information about progres-
sion of a lesion in patients without hypertension. I assume that
if the lesion progressed the patient would first become hyper-
tensive. A prospective study should be done.
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